CP 101 - Contera Pharma
Alternative Names: CP-101 - Contera PharmaLatest Information Update: 06 Feb 2024
At a glance
- Originator Contera Pharma
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metachromatic leukodystrophy
Most Recent Events
- 06 Feb 2024 Preclinical trials in Metachromatic leukodystrophy in Denmark (unspecified route), prior to February 2024 (Contera Pharma pipeline, February 2024)
- 28 Nov 2022 Early research in Metachromatic leukodystrophy in Denmark (unspecified route) (Contera Pharma pipeline, November 2022)